Which of the following drug can be given inhalationally for the diagnosis of bronchial hyperactivity in patients who do not have clinically apparent asthma?
**Core Concept**
The question is testing the concept of bronchial hyperresponsiveness, a hallmark of asthma, which can be objectively diagnosed using a methacholine challenge test. Methacholine is a cholinergic agonist that stimulates smooth muscle contraction, causing bronchoconstriction in susceptible individuals.
**Why the Correct Answer is Right**
Methacholine inhalation challenge is a widely used diagnostic tool for assessing bronchial hyperresponsiveness. When inhaled, methacholine binds to muscarinic receptors on airway smooth muscle cells, stimulating contraction and causing bronchoconstriction. The test is considered positive if a 20% or greater fall in forced expiratory volume in one second (FEV1) occurs within 15 minutes after inhalation of a cumulative dose of methacholine. This response is indicative of bronchial hyperresponsiveness, even in the absence of clinically apparent asthma.
**Why Each Wrong Option is Incorrect**
**Option A:** Histamine is another cholinergic agonist used in inhalation challenge tests, but it is less commonly used than methacholine due to its greater potency and potential for causing more severe reactions.
**Option B:** Salbutamol is a short-acting beta-2 agonist used for bronchodilation, but it is not used for diagnosing bronchial hyperresponsiveness.
**Option C:** Ipratropium is an anticholinergic agent used for bronchodilation, but it would not be useful for diagnosing bronchial hyperresponsiveness.
**Clinical Pearl / High-Yield Fact**
A positive methacholine challenge test can be an important diagnostic clue for asthma, even in patients without typical symptoms. The test can also help identify individuals with occult asthma who may benefit from preventive therapy.
**Correct Answer:** C. Methacholine.